HomeCompareIDRSF vs PM

IDRSF vs PM: Dividend Comparison 2026

IDRSF yields 48.90% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IDRSF wins by $322.6K in total portfolio value
10 years
IDRSF
IDRSF
● Live price
48.90%
Share price
$4.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$372.2K
Annual income
$74,100.38
Full IDRSF calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — IDRSF vs PM

📍 IDRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIDRSFPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IDRSF + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IDRSF pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDRSF
Annual income on $10K today (after 15% tax)
$4,156.48/yr
After 10yr DRIP, annual income (after tax)
$62,985.32/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, IDRSF beats the other by $60,867.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDRSF + PM for your $10,000?

IDRSF: 50%PM: 50%
100% PM50/50100% IDRSF
Portfolio after 10yr
$210.9K
Annual income
$38,296.20/yr
Blended yield
18.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

IDRSF
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-10.1
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDRSF buys
0
PM buys
0
No recent congressional trades found for IDRSF or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIDRSFPM
Forward yield48.90%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$372.2K$49.6K
Annual income after 10y$74,100.38$2,492.02
Total dividends collected$295.4K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: IDRSF vs PM ($10,000, DRIP)

YearIDRSF PortfolioIDRSF Income/yrPM PortfolioPM Income/yrGap
1← crossover$15,590$4,889.98$11,648$408.29+$3.9KIDRSF
2$23,806$7,124.73$13,589$495.90+$10.2KIDRSF
3$35,640$10,167.77$15,877$603.21+$19.8KIDRSF
4$52,361$14,226.41$18,580$734.88+$33.8KIDRSF
5$75,560$19,533.63$21,781$896.75+$53.8KIDRSF
6$107,194$26,344.00$25,578$1,096.12+$81.6KIDRSF
7$149,625$34,927.92$30,092$1,342.17+$119.5KIDRSF
8$205,663$45,564.28$35,470$1,646.46+$170.2KIDRSF
9$278,591$58,531.92$41,892$2,023.58+$236.7KIDRSF
10$372,193$74,100.38$49,578$2,492.02+$322.6KIDRSF

IDRSF vs PM: Complete Analysis 2026

IDRSFStock

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Full IDRSF Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this IDRSF vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDRSF vs SCHDIDRSF vs JEPIIDRSF vs OIDRSF vs KOIDRSF vs MAINIDRSF vs MOIDRSF vs BTIIDRSF vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.